VERAXA Biotech AG (NASDAQ: VRXA) has released new in vitro proof-of-concept data for its BiTAC(TM)-ADC technology platform, which aims to improve the precision of cancer treatment by restricting therapeutic activation to tumor cells. The company reported that BiTAC-ADCs can distinguish between breast cancer and healthy cells, achieving dose-dependent killing of 3D tumor cell spheroids while minimizing systemic toxicity through the use of separately delivered precursor components.
The findings, detailed in a press release, validate the platform's potential and complement VERAXA's BiTAC-TCE technology, giving the company two differentiated approaches for solid tumor indications. Management plans to discuss partnership opportunities for both platforms at the BIO International Convention in San Diego from June 22-25, 2026. For more details, the full press release is available at https://ibn.fm/QiPhH.
VERAXA Biotech focuses on developing next-generation antibody-based therapeutics, including bispecific T cell engagers and bispecific ADCs. The company leverages transformative technologies and quality-by-design principles to advance its pipeline. Founded on breakthroughs at the European Molecular Biology Laboratory (EMBL), VERAXA is positioned to address multiple cancer types. Updates on the company are available in its newsroom at http://ibn.fm/VRXA.
The BiTAC-ADC platform's ability to activate only in the tumor microenvironment represents a significant step forward in reducing off-target effects common with traditional ADCs. By using two separate components that combine only at the tumor site, the technology may allow for higher therapeutic doses with fewer side effects. This approach could be particularly relevant for cancers where healthy tissue damage limits treatment options.
As VERAXA prepares for the BIO International Convention, the company is seeking partners to further develop and commercialize its platforms. The oncology community will be watching closely to see how these preclinical data translate into clinical success. The announcement underscores the growing trend toward precision medicine in oncology, where therapies are designed to target cancer cells while sparing normal tissues.
